NEW YORK (TheStreet) -- After imploding by more than half from the start of the year, buying J.C. Penney (JCP) may feel like stepping out on railroad tracks and stopping a freight train with your hand.
If you're too early, your account can get trampled faster than you can say "margin call," as many have found out. That's the reason why I've been critical of J.C. Penney, especially after they blindsided investors with a 38% share dilution that sent shares falling to multi-year lows. But as the facts change, so must our opinion.
The financial situation is the same, not much has materially improved, but instead of paying over $10 a share, we can now buy the retailer for under $8.50. In fact, I will show you how you can lower your risk to under $7 a share while leaving room of a possible 10% gain in about three months.
Best Industrial Disributor Stocks To Invest In 2015: Theragenics Corporation(TGX)
Theragenics Corporation operates as a medical device company serving the cancer treatment and surgical products markets primarily in the United States and Europe. It operates through two segments, Surgical Products and Brachytherapy Seed. The Surgical Products segment manufactures, markets, and sells disposable devices primarily utilized in surgical procedures. It offers wound closure products, including sutures, needles, and other surgical products; vascular access products comprising introducer sheaths, guidewires, and accessories; and specialty needles consisting of coaxial, biopsy, brachytherapy, guidewire introducer, spinal, and disposable veress, as well as access trocars and other needle-based products. This segment?s products are used in various markets and applications, such as interventional cardiology and radiology, vascular surgery, orthopedics, plastic surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. The Brachytherapy See d segment manufactures, markets, and sells TheraSeed and I-Seed, which are FDA-cleared devices for treatment of solid localized tumors and localized prostate cancer. The company sells its products primarily to physicians, hospitals and other healthcare providers, original equipment manufacturers, and to a network of distributors. Theragenics Corporation was founded in 1981 and is based in Buford, Georgia.
Advisors' Opinion:- [By James E. Brumley]
I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).
10 Best Railroad Stocks To Buy Right Now: Redwood Trust Inc.(RWT)
Redwood Trust, Inc., a real estate investment trust, together with its subsidiaries, engages in investing, financing, and managing real estate assets. The company?s investments include residential and commercial real estate loans; and securities backed by residential and commercial loans, including senior and subordinate securities. The senior securities are those interests in a securitization that have the first right to cash flows and are last to absorb losses; and subordinate securities are those interests in a securitization that have the last right to cash flows and are first in line to absorb losses. As of March 31, 2011, it had 77 real estate owned properties primarily in Arizona, California, Colorado, Florida, and Georgia. It would elect to be taxed as a real estate investment trust (REIT) for federal income tax purposes. As a REIT, the company would not be subject to federal income tax, if it distributes at least 90% of net taxable income to its stockholders. Red wood Trust, Inc. was founded in 1994 and is based in Mill Valley, California.
Advisors' Opinion:- [By Amanda Alix]
On the mortgage front, Two Harbors notes that it has acquired a passel of prime jumbo home loans, which it likely plans to securitize. The company's CEO, Tom Siering, also addresses this issue on the earnings call, where he states that the trust was involved in a $400 million securitization of prime jumbo loans. This puts Two Harbors in the company of mREIT Redwood Trust (NYSE: RWT ) , which has nearly single-handedly brought back the jumbo-loan securitization market over the past two years. If Redwood's success is any indication -- it recently reported first-quarter net income�of $61 million, compared to the year-ago figure of $30 million -- Two Harbors is on the right track.
10 Best Railroad Stocks To Buy Right Now: Prothena Corporation PLC (PRTA)
Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company�� work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company�� program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tumor cells.
The Company�� pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.
NEOD001 for Amyloidosis
NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).
PRX002 for Parkinson�� Disease
The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkinson�� disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.
PRX003 for Inflammatory Diseases and Cancers
The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company�� antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.
Advisors' Opinion:- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) rose 24.40% to $46.23 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.
- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) shares surged 23.52% to touch a new 52-week high of $45.90 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.
- [By Jake L'Ecuyer]
Shares of Prothena Corporation plc (NASDAQ: PRTA) got a boost, shooting up 6.99 percent to $32.00 after the company reported the successful start of a Phase 1 clinical trial of PRX002 for the treatment of Parkinson's disease. Citigroup initiated coverage on the stock with a Buy rating and a $50.00 price target.
- [By Jake L'Ecuyer]
Prothena Corporation (NASDAQ: PRTA) shares were down as well, falling 28.00 percent to $27.13 after the company released some materials from its coming symposium presentation.
10 Best Railroad Stocks To Buy Right Now: Novo Nordisk A/S (NVO)
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes care segment covers insulins, oral antidiabetic drugs, and other protein-related products and projects comprising glucagon and protein-related delivery systems, as well as GLP-1 analogue. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation therapy. Its products are marketed and distributed through subsidiaries, distributors, and independent agents in 180 countries. Novo Nordisk A/S has a collaboration agreement with Archimedes, Inc. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Advisors' Opinion:- [By Dan Carroll]
Novo Nordisk (NYSE: NVO ) is one of the best examples of how a company has succeeded in China. It has dominated China's diabetes market -- a market that �Novo Nordisk estimated at 93 million total diabetic Chinese patients last year. With diabetes prevalence rising in China, Novo has carved out a 37% market share in the niche, more than double that of its nearest rival, Bayer. Novo's Chinese sales grew by 28% last year, and if the company can maintain its hold in the diabetes market, its stock -- which has slumped into the red in 2013 but is up nearly 150% over the last five years -- will rise on the back of China's growing pharmaceutical needs.
10 Best Railroad Stocks To Buy Right Now: Arkema SA (AKE)
Arkema SA is a France-based company which specializes in the manufacture and marketing of chemical products. The Company operates through its two business segments: Industrial Chemicals and Performance Products. The Industrial Chemicals division offers the production of acrylics, polymethyl methacrylate (PMMA), hydrogen peroxide, fluorochemicals and thiochemicals, and includes such brands as Forane, Albone, Norsocryl, Altuglas and Sarbio. The Performance Products include the production of technical polymers, specialty chemicals and functional additives. The Company's products are used in the construction, automotive and transportation, health, electrical and electronics, agricultural and packaging industries, among others. In April 2013, it acquired a majority stake in AEC Polymers. In October 2013, it inaugurated the new Sumitomo Seika superabsorbent plant on the Carling site, which makes the overall superabsorbent production capacity of the Carling facility up to 47,000 ton/year. Advisors' Opinion:- [By Inyoung Hwang]
Arkema SA (AKE) added 4.7 percent to 83.93 euros. UBS AG raised its rating on the French chemicals maker to a buy from neutral, saying the stock is undervalued. The firm also boosted its price target to 100 euros from 80 euros.
10 Best Railroad Stocks To Buy Right Now: Toll Brothers Inc.(TOL)
Toll Brothers, Inc., together with its subsidiaries, designs, builds, markets, and arranges finance for single-family detached and attached homes in luxury residential communities. It is also involved in building or converting existing rental apartment buildings into high-, mid-, and low-rise luxury homes. In addition, the company develops, owns, and operates golf courses and country clubs associated with various planned communities, as well as individual communities. It serves move-up, empty-nester, active-adult, age-qualified, and second-home buyers in 19 states in the United States. Toll Brothers, Inc. was founded in 1967 and is headquartered in Horsham, Pennsylvania.
Advisors' Opinion:- [By Anora Mahmudova]
Shares in KB Home (KBH) �fell 2.7%, while Toll Brothers�� (TOL) �shares lost 1.6%.
- [By Susan J. Aluise]
A�rebounding construction market drove rival Toll Brothers (TOL), which reported earnings last Wednesday, to double its quarterly profit. The same trends should positively impact LEN stock, but with a bonus: Last year, LEN revealed it was allocating $1 billion to building apartments in high-growth — and high rent — areas.� Many of the new communities offer luxury amenities such as stainless steel appliances, granite countertops and resort-style pools and fitness centers –�directly catering to the new generation of renters.
- [By Sue Chang]
Toll Brothers (TOL) �is forecast to post fiscal-second-quarter earnings of 27 cents a share. The stock is rated underperform with a price target of $28 at Sterne Agee.
10 Best Railroad Stocks To Buy Right Now: ProShares Short FTSE Xinhua China 25 (YXI)
ProShares Short FTSE China 25 (the Fund) is an exchange-traded fund. The Fund seeks daily investment results that correspond to the inverse (opposite) of the daily performance of the FTSE/Xinhua China 25 Index (the Index). The Index consists of 25 of the largest and most liquid Chinese stocks listed on the Hong Kong Stock Exchange. This free float adjusted Index caps the weight of any of constituent stock at 10% to ensure broad representation of the Chinese economy. The Fund seeks investment results for a single day only, not for longer periods. The Index is compiled and calculated by FTSE International Limited (FTSE) on behalf of FTSE/Xinhua Index Limited (FXI). The Fund will typically concentrate its investments in issuers of one or more particular industries to the same extent that its underlying Index is so concentrated. The Fund�� investment advisor is ProShare Advisors LLC. Advisors' Opinion:- [By pamatlarge]
Three short ETFs are designed to profit from China�� economic downward slide. The ProShares Short FTSE China 25 (YXI), an unleveraged ETF, holds shares in iShares FTSE China Large-Cap (FXI) swaps. Investors looking to magnify their returns can choose from two leveraged short ETFs: ProShares Ultra Short FTSE China 25 (FXP) and Direxion Daily China Bear 3x Shares (YANG). Both ProShares Ultra Short and Direxion Daily hold shares that increase in value three times faster than an unleveraged ETF. The downside is that the per share price of these leveraged ETFs also drops three times faster.
No comments:
Post a Comment